GSK presents positive data for AREXVY, its respiratory syncytial virus (RSV) vaccine, indicating protection over three RSV ...

GSK plc (GSK, GSK.L) announced Tuesday new data from the AReSVi-006 (Adult Respiratory Syncytial Virus) phase III trial evaluating ...

Pfizer Inc. (NYSE:PFE) stock is trading higher with a session volume of 31.16 million as per data from Benzinga Pro. Activist investor Starboard Value has invested approximately $1 billion in Pfizer ...

Respiratory Virus Hospitalization Surveillance Network (RESP-NET) is made up of three networks that monitor COVID-19, ...

GSK said on Tuesday that its Arexvy respiratory syncytial virus vaccine was 43.3% effective in preventing severe illness in ...

While recent CDC guidance threatens to shrink the market for a new class of immunizations, GSK continues to build the case ...

GSK: Some independent pharmacists said demand during the autumn vaccination season for respiratory syncytial virus shots has ...

In most cases, adequate hydration and over-the-counter pain relievers can help manage your symptoms during the week or two it ...

GSK said data from a late-phase study showed that its respiratory syncytial virus vaccine, Arexvy, granted protection over three full RSV seasons.

Immunization appointments are now open for eligible Albertans. As of Monday (Oct. 7) both COVID-19 and influenza immunization ...

Cumulatively, data showed the shot to be 63% effective across the three-year period. However, efficacy appeared to wane and GSK said it expects revaccination will eventually be needed.

Now that it’s autumn, many will be dodging illnesses like COVID, Influenza, Respiratory Syncytial Virus (RSV), and other ...